loadpatents
Patent applications and USPTO patent grants for ARMITAGE; RICHARD J..The latest application filed is for "human cd30 ligand antigen binding proteins".
Patent | Date |
---|---|
Human Cd30 Ligand Antigen Binding Proteins App 20220112295 - ANDERSEN; METTE D. ;   et al. | 2022-04-14 |
BCMA antigen binding proteins Grant 10,465,009 - Armitage , et al. No | 2019-11-05 |
BCMA Antigen binding proteins Grant 10,220,090 - Armitage , et al. | 2019-03-05 |
Use Of Interleukin-4 Antagonists And Compositions Thereof App 20190023798 - Armitage; Richard J. ;   et al. | 2019-01-24 |
Bcma Antigen Binding Proteins App 20190008974 - ARMITAGE; Richard J. ;   et al. | 2019-01-10 |
Human CD30 Ligand Antigen Binding Proteins App 20180298105 - Andersen; Mette D. ;   et al. | 2018-10-18 |
Use Of Interleukin-4 Antagonists And Compositions Thereof App 20180171016 - ARMITAGE; Richard J. ;   et al. | 2018-06-21 |
Human CD30 ligand antigen binding proteins Grant 9,926,373 - Andersen , et al. March 27, 2 | 2018-03-27 |
Bcma Antigen Binding Proteins App 20170165373 - ARMITAGE; Richard J. ;   et al. | 2017-06-15 |
Use Of Interleukin-4 Antagonists And Compositions Thereof App 20170137526 - ARMITAGE; Richard J. ;   et al. | 2017-05-18 |
Anti-interleukin-4 receptor antibodies Grant 9,587,026 - Armitage , et al. March 7, 2 | 2017-03-07 |
Human CD30 Ligand Antigen Binding Proteins App 20160039940 - Andersen; Mette D. ;   et al. | 2016-02-11 |
BCMA antigen binding proteins Grant 9,243,058 - Armitage , et al. January 26, 2 | 2016-01-26 |
Bcma Antigen Binding Proteins App 20150344583 - ARMITAGE; Richard J. ;   et al. | 2015-12-03 |
Bcma Antigen Binding Proteins App 20140161828 - ARMITAGE; Richard J. ;   et al. | 2014-06-12 |
Use Of Interleukin-4 Antagonists And Compositions Thereof App 20140154267 - ARMITAGE; Richard J. ;   et al. | 2014-06-05 |
Anti-interleukin-4 receptor antibodies Grant 8,679,487 - Armitage , et al. March 25, 2 | 2014-03-25 |
ULBP2 polypeptides Grant 8,410,252 - Cosman , et al. April 2, 2 | 2013-04-02 |
Use Of Interleukin-4 Antagonists And Compositions Thereof App 20110002913 - ARMITAGE; RICHARD J. ;   et al. | 2011-01-06 |
ULBP antibodies Grant 7,807,796 - Cosman , et al. October 5, 2 | 2010-10-05 |
CD30 Ligand App 20090264349 - Goodwin; Raymond G. ;   et al. | 2009-10-22 |
CD40-Ligand lacking native-pattern glycosylation Grant 7,405,270 - Armitage , et al. July 29, 2 | 2008-07-29 |
Mouse CD40 ligand-specific antibodies and hybridomas Grant 7,309,489 - Armitage , et al. December 18, 2 | 2007-12-18 |
CD30 ligand Grant 7,232,660 - Goodwin , et al. June 19, 2 | 2007-06-19 |
CD 30 ligand App 20040241758 - Goodwin, Raymond G. ;   et al. | 2004-12-02 |
CD40-Ligand lacking native-pattern glycosylation App 20040006006 - Armitage, Richard J. ;   et al. | 2004-01-08 |
CD30 ligand Grant 6,667,039 - Goodwin , et al. December 23, 2 | 2003-12-23 |
Defective CD4+T-cells that express active CD40-L Grant 6,613,320 - Spriggs , et al. September 2, 2 | 2003-09-02 |
CD40-Ligand lacking native-pattern glycosylation App 20030144182 - Armitage, Richard J. ;   et al. | 2003-07-31 |
Methods Of Treating An Undesired Immune Response By Blocking The Binding 0f Cd40 Ligand To Cd40 App 20030091564 - ARMITAGE, RICHARD J. ;   et al. | 2003-05-15 |
DNA encoding CD40 ligand, a cytokine that binds CD40 Grant 6,410,711 - Armitage , et al. June 25, 2 | 2002-06-25 |
Use of CD40 ligand, a cytokine that binds CD40, to stimulate hybridoma cells Grant 6,391,637 - Armitage , et al. May 21, 2 | 2002-05-21 |
Method of augmenting a vaccine response by administering CD40 ligand Grant 6,290,972 - Armitage , et al. September 18, 2 | 2001-09-18 |
Methods of inhibiting CD40L binding to CD40 with soluble monomeric CD40L Grant 6,264,951 - Armitage , et al. July 24, 2 | 2001-07-24 |
CD30 ligand oligomers and polypeptides Grant 6,143,869 - Goodwin , et al. November 7, 2 | 2000-11-07 |
CD40 ligand polypeptide Grant 6,087,329 - Armitage , et al. July 11, 2 | 2000-07-11 |
DNA encoding CD40 ligand, a cytokine that binds CD40 Grant 5,981,724 - Armitage , et al. November 9, 1 | 1999-11-09 |
Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same Grant 5,962,406 - Armitage , et al. October 5, 1 | 1999-10-05 |
Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same Grant 5,961,974 - Armitage , et al. October 5, 1 | 1999-10-05 |
Isolated Epstein-Barr virus BZLF2 proteins that bind MHC class II .beta.chains Grant 5,925,734 - Alderson , et al. July 20, 1 | 1999-07-20 |
Antibodies to CD40 Grant 5,801,227 - Fanslow, III , et al. September 1, 1 | 1998-09-01 |
Isolated epstein-barr virus BZLF2 proteins that bind MHC class II beta chains Grant 5,726,286 - Alderson , et al. March 10, 1 | 1998-03-10 |
CD27 ligand Grant 5,573,924 - Beckmann , et al. November 12, 1 | 1996-11-12 |
Detection of mutations in a CD40 ligand gene Grant 5,565,321 - Spriggs , et al. October 15, 1 | 1996-10-15 |
CD30 ligand Grant 5,480,981 - Goodwin , et al. January 2, 1 | 1996-01-02 |
Interleukin-4 binding protein-.gamma. Grant 5,223,605 - Fanslow , et al. June 29, 1 | 1993-06-29 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.